AltPep

Executive Summary

AltPep is a privately-held biotechnology company headquartered in Seattle, Washington, dedicated to developing early disease-modifying therapeutics and diagnostic tools for amyloid diseases, including Alzheimer’s and Parkinson’s. The company’s innovative platform targets toxic soluble oligomers—the early molecular triggers of neurodegeneration—by employing custom-designed synthetic peptides that selectively bind to a unique protein structure known as α-sheet. This approach aims to intercept disease progression at its earliest stages, offering potential for both treatment and early detection. Founded in 2018, AltPep has remained under the radar but is poised to address significant unmet needs in neurodegenerative conditions, where current therapies are largely symptomatic and late-stage interventions.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 1 Clinical Trial for Lead Alzheimer’s Candidate65% success
• Q3 2026Series A Financing Round to Support Pipeline Expansion80% success
• H2 2026Publication of Peer-Reviewed Preclinical Data on α-Sheet Targeting90% success